Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $22.66, for a total value of $22,660.00. Following the sale, the chief financial officer owned 23,000 shares in the company, valued at approximately $521,180. This trade represents a 4.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Benjamin Hohl also recently made the following trade(s):

• On Friday, June 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.91, for a total value of $67,957.50.
• On Tuesday, May 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.18, for a total value of $52,585.00.
• On Monday, April 28th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.69, for a total value of $60,742.50.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded up $0.88 during midday trading on Thursday, hitting $22.34. 115,924 shares of the company traded hands, compared to its average volume of 303,334. The company has a market cap of $1.10 billion, a PE ratio of -11.64 and a beta of 0.83. The company's 50-day simple moving average is $19.93 and its 200-day simple moving average is $20.28. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ELVN shares. Robert W. Baird upped their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price objective on the stock. HC Wainwright increased their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Finally, Jones Trading dropped their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Enliven Therapeutics has an average rating of "Buy" and an average price target of $41.20.

Institutional Trading of Enliven Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ELVN. Polar Capital Holdings Plc lifted its holdings in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after purchasing an additional 1,739,668 shares during the last quarter. Boxer Capital Management LLC purchased a new position in Enliven Therapeutics in the 4th quarter worth $15,106,000. Janus Henderson Group PLC raised its stake in Enliven Therapeutics by 27.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after acquiring an additional 290,153 shares during the last quarter. FMR LLC raised its stake in Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after acquiring an additional 199,692 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its stake in Enliven Therapeutics by 16.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after acquiring an additional 135,969 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.